Why Are Windtree Therapeutics Shares Trading Higher Today?

Comments
Loading...

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 of 2022.

  • The 20-subject Phase 2 trial is designed to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in mechanically ventilated patients due to this COVID-19 associated acute lung injury. 
  • Functional changes in gas exchange and lung compliance are also being measured.
  • Lucinactant is a synthetic surfactant structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 (sinapultide). 
  • This 21-amino acid peptide is designed to imitate the human surfactant protein B (SP-B). S
  • Price Action: WINT shares are up 21.20% at $1.37 during the market session on the last check Tuesday.
WINT Logo
WINTWindtree Therapeutics Inc
$1.308.33%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
0.12
Growth
-
Quality
-
Value
-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: